Venetoclax-enhanced reduced-intensity conditioning in older patients aged >= 55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.
Older patients with high-risk blood cancers achieved strong 73% one-year survival with a modified chemotherapy regimen, offering improved outcomes.
Venetoclax-enhanced RIC (VEN-RIC) in older high-risk AML/MDS patients (>=55y) yielded 1-year PFS 72.5%, OS 73.8%, and NRM 10.6% with manageable toxicity; TP53 mutation was the strongest predictor of worse outcomes. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- phase II single-arm prospective trial (n=50, median age 62)
- Category
- hematologic_malignancies
- Maturity
- Validated
- Journal
- Br J Haematol
Why it surfaced
Phase II evidence for VEN-RIC in older high-risk myeloid malignancy patients—a large, therapeutically challenging population—providing encouraging survival data for this novel conditioning approach.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.